Development and evaluation of a pharmaceutical care program to reduce modifiable risk of chronic complications in brazilian type 2 diabetic patients
In this study we developed and evaluated a pharmaceutical care program (PCP) to reduce modifiable risk factors of chronic complications of type 2 diabetes. Patients who acquired their anti-diabetic drugs from a Brazilian community pharmacies chain were invited to participate in the PCP. The recrui...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Articulo |
| Lenguaje: | Inglés |
| Publicado: |
2011
|
| Materias: | |
| Acceso en línea: | http://sedici.unlp.edu.ar/handle/10915/8115 http://www.latamjpharm.org/resumenes/30/1/LAJOP_30_1_1_23.pdf |
| Aporte de: |
| Sumario: | In this study we developed and evaluated a pharmaceutical care program (PCP) to reduce
modifiable risk factors of chronic complications of type 2 diabetes. Patients who acquired their anti-diabetic
drugs from a Brazilian community pharmacies chain were invited to participate in the PCP. The recruited
patients were monthly interviewed and information about pharmacotherapy, comorbidities, diet,
physical activity, body mass index (BMI), blood pressure (BP), and waist circumference (WC) were obtained.
Evaluation of glycemia, glycated hemoglobin A1c (HbA1c), and lipid profile analyses was done after
the first interview and repeated every four months until finish the PCP. The 51 (91.1 %) patients who
completed the PCP (12 months) showed improvement in the nutritional habits, physical activity, pharmacoterapeutic
follow-up, HbA1c, lipid profile, BP, WC, and BMI. Thus, the PCP was applicable to the type
2 diabetic patients improving diabetes education and reducing modifiable risk factors of chronic complications. |
|---|